XNAS · ALMS
+2.73% · +$0.1900 · Vol Not reported
Pre-market · updated 04:14:15 ET
Alumis Inc. Common Stock

Alumis Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$7.16
Card
Relationship Map

Follow $ALMS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ALMS by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
ALMS
Alumis Inc. Common Stock
Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

41/ 100
Veridion Score
Lower range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALMS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALMS catalysts
About Alumis Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
239
Country
US

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.97
Last session
Day high
$6.97
Last session
Day low
$6.97
Last session
Previous close
$6.97
52W high
$30.30
-76.37% from high
52W low
$4.44
11% of range
Market cap
$902.2M
Beta
2.33
Shares out
129.4M
Avg volume
4.1M
VWAP
$6.97
Last session
Price history computed in-house
1W
+4.53%
1M
-26.94%
3M
-74.71%
1Y
+58.06%
YTD
-26.64%
SMA 50 $16.09 · below
SMA 200 $22.04 · below
52W position 11%

ALMS overview

Veridion Score
41
Registered · 2026-10-08
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALMS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALMS Form 4 filings
Public disclosures

Congress activity in ALMS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ALMS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALMS in this window.
Lobbying spend

ALMS lobbying filings, year to date.

Registered lobbying filings matched to Alumis Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALMS in this window.
Loading news for ALMS
Analyst ratings
Sovereign unlock shows live analyst consensus for ALMS.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.